Korean J Urol.  1990 Dec;31(6):814-819.

M-VAC and MAC Combination Chemotherapy in Advanced Bladder Cancer

• Kang HG
• Chang JH

Abstract

Of the 11 advanced bladder cancer patients who received M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) combination chemotherapy, complete and partial remission were observed in 63.6%. Of the 17 advanced bladder cancer patients who received MAC (Methotrexate, Doxorubicin and Cisplatin) combination chemotherapy, complete and partial remissions were observed in 17%. Complete remission was achieved in 18.2% of the patients clinically, pathologically in M-VAC group and 5.9% in MAC group. Partial remission was occurred in 46.5% of the patients in M-VAC group and 41.2% in MAC group. All metastatic sites including the bone and liver, lung were well responded in M-VAC group, but poorly responded in MAC group. Toxicity was significant but tolerable.

Keyword

Advanced bladder tumor; M-VAC and MAC combination chemotherapy

MeSH Terms

Doxorubicin
Drug Therapy, Combination*
Humans
Liver
Lung
Urinary Bladder Neoplasms*
Urinary Bladder*
Vinblastine
Doxorubicin
Vinblastine